Literature DB >> 18374419

In vitro measurements of metabolism for application in pharmacokinetic modeling.

John C Lipscomb1, Torka S Poet.   

Abstract

Human risk and exposure assessments require dosimetry information. Species-specific tissue dose response will be driven by physiological and biochemical processes. While metabolism and pharmacokinetic data are often not available in humans, they are much more available in laboratory animals; metabolic rate constants can be readily derived in vitro. The physiological differences between laboratory animals and humans are known. Biochemical processes, especially metabolism, can be measured in vitro and extrapolated to account for in vivo metabolism through clearance models or when linked to a physiologically based pharmacological (PBPK) model to describe the physiological processes, such as drug delivery to the metabolic organ. This review focuses on the different organ, cellular, and subcellular systems that can be used to measure in vitro metabolic rate constants and how those data are extrapolated to be used in biologically based modeling. NOTICE: The views expressed in this paper are those of the authors and do not necessarily reflect the views and policies of the U.S. Environmental Protection Agency. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18374419     DOI: 10.1016/j.pharmthera.2008.01.006

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  10 in total

1.  In vitro characterization of rosiglitazone metabolites and determination of the kinetic parameters employing rat liver microsomal fraction.

Authors:  Leandro Augusto Calixto; Anderson Rodrigo Moraes de Oliveira; Valquíria Aparecida Polisel Jabor; Pierina Sueli Bonato
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-04-17       Impact factor: 2.441

2.  Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening.

Authors:  Shaun P Brothers; S Adrian Saldanha; Timothy P Spicer; Michael Cameron; Becky A Mercer; Peter Chase; Patricia McDonald; Claes Wahlestedt; Peter S Hodder
Journal:  Mol Pharmacol       Date:  2009-10-16       Impact factor: 4.436

Review 3.  Considerations for Improving Metabolism Predictions for In Vitro to In Vivo Extrapolation.

Authors:  Marjory Moreau; Pankajini Mallick; Marci Smeltz; Saad Haider; Chantel I Nicolas; Salil N Pendse; Jeremy A Leonard; Matthew W Linakis; Patrick D McMullen; Rebecca A Clewell; Harvey J Clewell; Miyoung Yoon
Journal:  Front Toxicol       Date:  2022-04-29

Review 4.  IVIVE: Facilitating the Use of In Vitro Toxicity Data in Risk Assessment and Decision Making.

Authors:  Xiaoqing Chang; Yu-Mei Tan; David G Allen; Shannon Bell; Paul C Brown; Lauren Browning; Patricia Ceger; Jeffery Gearhart; Pertti J Hakkinen; Shruti V Kabadi; Nicole C Kleinstreuer; Annie Lumen; Joanna Matheson; Alicia Paini; Heather A Pangburn; Elijah J Petersen; Emily N Reinke; Alexandre J S Ribeiro; Nisha Sipes; Lisa M Sweeney; John F Wambaugh; Ronald Wange; Barbara A Wetmore; Moiz Mumtaz
Journal:  Toxics       Date:  2022-05-01

5.  A Workflow for Global Sensitivity Analysis of PBPK Models.

Authors:  Kevin McNally; Richard Cotton; George D Loizou
Journal:  Front Pharmacol       Date:  2011-06-23       Impact factor: 5.810

6.  Development of screening tools for the interpretation of chemical biomonitoring data.

Authors:  Richard A Becker; Sean M Hays; Steven Robison; Lesa L Aylward
Journal:  J Toxicol       Date:  2012-02-16

Review 7.  Arsenic toxicokinetic modeling and risk analysis: Progress, needs and applications.

Authors:  Elaina M Kenyon
Journal:  Toxicology       Date:  2021-05-07       Impact factor: 4.571

8.  The application of global sensitivity analysis in the development of a physiologically based pharmacokinetic model for m-xylene and ethanol co-exposure in humans.

Authors:  George D Loizou; Kevin McNally; Kate Jones; John Cocker
Journal:  Front Pharmacol       Date:  2015-06-30       Impact factor: 5.810

Review 9.  Animal-Free Chemical Safety Assessment.

Authors:  George D Loizou
Journal:  Front Pharmacol       Date:  2016-07-21       Impact factor: 5.810

10.  Characterization of furathiocarb metabolism in in-vitro human liver microsomes and recombinant cytochrome P450 enzymes.

Authors:  Khaled Abass; Petri Reponen; Walaa F Alsanie; Arja Rautio; Olavi Pelkonen
Journal:  Toxicol Rep       Date:  2022-04-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.